应用特瑞普苏单抗-德鲁祖替加治疗HER2阳性乳腺癌和蛛网膜下转移病人出现持久缓解。
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan.
发表日期：2023 Mar 30
作者：
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E D Van Swearingen, Sara M Tolaney, Mustafa Khasraw, Carey K Anders, Christopher D Lascola, Liangge Hsu, Nancy U Lin, Sarah Sammons
来源：
npj Breast Cancer
摘要：
Leptomeningeal metastases (LM) 是 HER2+转移性乳腺癌 (MBC) 的严重并发症，目前没有有效的治疗方法。在8例重度预处理的 HER2+ MBC 和进展性 LM 的病例系列中，所有8例患者 (100%) 从 Trastuzumab deruxtecan (TDXd) 中获得了临床效益，4例患者 (50%) 基于正式神经放射学 MRI 读数使用 EORTC/RANO-LM 修订版记分卡具有客观部分反应。在 HER2+ MBC 和 T-DXd 可能处于活跃状态的实体瘤中，T-DXd 值得进一步研究。© 2023. 作者们。
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.© 2023. The Author(s).